T2DM (Type 2 Diabetes Mellitus) Clinical Trial
Official title:
Comparison of 3 Versus 6-Month Use of Professional Continuous Glucose Monitoring in the Treatment of Poorly Controlled, Non-Insulin Using T2DM Patients in a Primary Care Setting
To determine whether 3-month versus 6-month professional CGM utilization improves time spent in target range of 70-140mg/dl in patients with poorly controlled T2DM not treated with insulin.
Patients not receiving any insulin treatment with an HbA1c ≥ 7.5% before their scheduled primary care appointment will be invited to participate in the study and wear professional CGM for at least 3 days at either 3 intervals (baseline, 3-month and 6-month) or 2 intervals (baseline and 6-month). After removal, the downloaded report will provide quantitative data to determine the percent of time spent in the target range. The 6-month data will be analyzed to determine if frequency of professional CGM wear positively affects time spent in target range. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01373814 -
Nutritional Therapy for Diabetic Cardiomyopathy
|
||
Recruiting |
NCT05469659 -
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
|
Phase 2 | |
Completed |
NCT05376930 -
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.
|
Phase 3 | |
Recruiting |
NCT04682795 -
Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM
|
N/A | |
Recruiting |
NCT06350890 -
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04634500 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
|
Phase 3 | |
Recruiting |
NCT03789695 -
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
|
Phase 4 | |
Completed |
NCT04632862 -
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
|
Phase 3 | |
Completed |
NCT04688359 -
Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM
|
N/A | |
Completed |
NCT05983289 -
Single Escalating Dose Study Of HSK7653 In Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04272359 -
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
|
||
Completed |
NCT03467932 -
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT05376969 -
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
|
Phase 3 | |
Recruiting |
NCT06415773 -
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
|
Phase 3 | |
Recruiting |
NCT06094491 -
Virtual Diabetes Group Visits Across Health Systems
|
Phase 2 | |
Completed |
NCT05279911 -
Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion
|
N/A | |
Active, not recruiting |
NCT03257449 -
Effect of Viscous Soluble Fibres on Body Weight
|
N/A | |
Terminated |
NCT04754334 -
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
|
Phase 3 | |
Not yet recruiting |
NCT06293417 -
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
|
||
Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 |